EDX Medical Group PLC
28 September 2026
28 September 2026
EDX Medical Group plc
("EDX Medical" or the "Company")
Results of Annual General Meeting
CAMBRIDGE, UK: EDX Medical (TIDM: EDX), which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, today announces the results of its Annual General Meeting, held at the Henrietta Room, 1 Wimpole Street, London, W1G 0AE on 28 September 2026 at 2.00 p.m.
All resolutions were passed as a poll. Resolutions 1 - 11 were passed as ordinary resolutions and resolutions 12 and 13 were passed as special resolutions.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary) To receive the Annual Report and Accounts of the Company for the year ended 31 March 2026 together with the Directorsʼ reports and auditorʼs report on those accounts. |
181,843,821 |
100.00 |
0 |
0 |
7,720,023 |
|
Resolution 2 (Ordinary) To accept the Remuneration Committee Report for the financial year ended 31 March 2026, as set out in the Company's Annual Report and Accounts for the year ended 31 March 2026. |
181,841,341 |
>99.99 |
2,480 |
<0.01 |
7,720,023 |
|
Resolution 3 (Ordinary) To accept the Directorsʼ Remuneration Policy, as set out in the Company's Annual Report and Accounts for the year ended 31 March 2026. |
169,927,624 |
>99.99 |
2,459 |
<0.01 |
19,633,761 |
|
Resolution 4 (Ordinary) To re-appoint Jason Holt as a director of the Company. |
181,840,525 |
>99.99 |
2,517 |
<0.01 |
7,720,802 |
|
Resolution 5 (Ordinary) To re-appoint Dr Michael Hudson as a director of the Company. |
181,841,125 |
>99.99 |
2,433 |
<0.01 |
7,720,286 |
|
Resolution 6 (Ordinary) To re-appoint Professor Sir Christopher Evans as a director of the Company. |
181,841,143 |
>99.99 |
2,433 |
<0.01 |
7,720,268 |
|
Resolution 7 (Ordinary) To re-appoint Professor Trevor Jones as a director of the Company. |
181,841,085 |
>99.99 |
2,473 |
<0.01 |
7,720,286 |
|
Resolution 8 (Ordinary) To re-appoint Martin Walton as a director of the Company. |
181,841,085 |
>99.99 |
2,473 |
<0.01 |
7,720,286 |
|
Resolution 9 (Ordinary) To re-appoint PKF Littlejohn LLP as auditor of the Company. |
181,839,576 |
100.00 |
0 |
0 |
7,724,268 |
|
Resolution 10 (Ordinary) To authorise the Directors to determine the fees payable to the auditor |
181,839,494 |
>99.99 |
82 |
<0.01 |
7,724,268 |
|
Resolution 11 (Ordinary) To authorise the Directors to allot shares in the Company. |
181,818,769 |
99.99 |
19,273 |
0.01 |
7,725,802 |
|
Resolution 12 (Special) To disapply statutory pre-emption rights generally. |
181,229,094 |
99.66 |
609,421 |
0.34 |
7,725,329 |
|
Resolution 13 (Special) To disapply statutory pre-emption rights pursuant to an acquisition or other capital investment. |
181,080,100 |
99.69 |
567,026 |
0.31 |
7,916,718 |
As at 28 September 2026, there were 431,373,146 ordinary shares in issue with no shares held in treasury, resulting in total voting rights of 431,373,146. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
For enquiries, please contact:
|
EDX Medical Group plc |
|
|
Dr Mike Hudson (Chief Executive Officer) |
+44 (0)7812 345 301 |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Stuart Andrews |
+44 (0) 20 7523 8318 |
|
Media House International |
|
|
Ramsay Smith Gary McQueen |
+44 (0)7788 414856 + 44 (0)7834 694609 |
|
IFC Advisory (Investor Relations) |
|
|
Graham Herring Tim Metcalfe |
+44 (0) 203 934 6630 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.